Surrogate markers for targeted therapy-based treatment activity and efficacy

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 91-94

  Bianchini, Giampaolo ^a   Gianni, Luca ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; LAPATINIB; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EFFICACY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MOLECULAR THERAPY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; TREATMENT RESPONSE; VALIDATION PROCESS; ADJUVANT THERAPY; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; KI-67 ANTIGEN; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 84855183280     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr024     Document Type: Article

References (26)

1. Bianchini G, Gianni L. Introducing new molecular technologies into routine clinical cancer care:is there an impact on the treatment of breast cancer? Ann Oncol. 2008, 19(suppl 7): vii177-vii183.
2. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010, 28(20): 3366-3379.
3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007, 25(33): 5287-5312.
4. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007, 99(2): 147-157.
5. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2(3): e73.
6. Gast MC, Schellens JH, Beijnen JH. Clinical proteomics in breast cancer:a review. Breast Cancer Res Treat. 2009, 116(1): 17-29.
7. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007, 25(28): 4414-4422.
8. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008, 100(19): 1380-1388.
9. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H):antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Cancer Res. 2010, 70(24 suppl): Abstract S3-2.
10. Dowsett M, Dixon JM, Horgan K, et al. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res. 2000, 6(6): 2260-2267.
11. Guix M, Granja Nde M, Meszoely I, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008, 26(6): 897-906.
12. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers:design issues. J Natl Cancer Inst. 2010, 102(3): 152-160.
13. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12(11): 1294-1300.
14. Moulder S, Yan K, Huang F, et al. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Mol Cancer Ther. 2010, 9(5): 1120-1127.
15. Coombes KR, Wang J, Baggerly KA. Microarrays:retracing steps. Nat Med. 2007, 13(11): 1276-1277,author reply 1277-1278.
16. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439(7074): 353-357.
17. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007, 104(18): 7564-7569.
18. Crowder RJ, Phommaly C, Tao Y, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009, 69(9): 3955-3962.
19. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 2003, 63(19): 6523-6531.
20. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status:an hypothesis-generating study. J Clin Oncol. 2005, 23(30): 7512-7517.
21. Kuter I, Sapunar F, McCormack P. Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg:results from the NEWEST study. J Clin Oncol. 2008, 26(suppl): Abstract 579.
22. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007, 99(8): 628-638.
23. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. 2008, 26(7): 1066-1072.
24. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007, 12(4): 395-402.
25. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68(15): 6084-6091.
26. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer:a proof-of-concept trial. Lancet. 2010, 376(9737): 235-244.